With its oversea partner (US.SMMT) breakout and achieve 10x in a year, I think HK9926 is likely to breakout and extend its range, to form a leg, from current long term range.
HK9926 still have momentum and see if it can breakout through this momentum, I think currently is still a buy.
There are still some catalyst coming this september and see if it can hold this current price range above $60.
But I won't chace SMMT as it is over-extended in weekly timeframe and could experience a retracement.
Note
after a range bound for some while, is this going to be a trend continuation?Note
Trend continuation now, the earnings result are really good, CEO is positive about its AK112 to become the best-in-class drug in its field globally. sq&nsq NSCLC, MSSmCRC are big market, it can compete with Keytruda. Also If NSCLC test coming out in mid-year is positive, it could apply for US FDA and sell globally, not just in China.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.